Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.20 million during the quarter. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Performance

Shares of NASDAQ SMMT traded down $13.23 during mid-day trading on Friday, reaching $23.47. The company had a trading volume of 24,583,288 shares, compared to its average volume of 3,782,034. The stock has a fifty day moving average of $20.95 and a two-hundred day moving average of $20.15. The company has a market capitalization of $17.31 billion, a price-to-earnings ratio of -83.82 and a beta of -0.46. Summit Therapeutics has a 12-month low of $2.10 and a 12-month high of $36.91.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Jefferies Financial Group set a $44.00 price target on shares of Summit Therapeutics and gave the stock a "buy" rating in a research report on Friday. Cantor Fitzgerald reissued an "overweight" rating on shares of Summit Therapeutics in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $44.00 price objective on shares of Summit Therapeutics in a research report on Tuesday, February 25th. Evercore ISI started coverage on shares of Summit Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $30.00 price objective on the stock. Finally, Summit Redstone set a $35.00 price objective on shares of Summit Therapeutics in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.70.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.